Trichoscopic Predictors of Treatment Response in Tinea Capitis: A Prospective Study
NCT ID: NCT07043582
Last Updated: 2025-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
150 participants
OBSERVATIONAL
2025-07-24
2025-10-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this observational study is to learn how well changes seen under a special microscope called a trichoscope (used to look at hair and scalp) match the success of treatment in children and adolescents with a scalp fungal infection called tinea capitis. The main questions it aims to answer are:
Do changes in trichoscopic findings show when the fungal infection is cured?
Does having more severe trichoscopic findings at the start mean that treatment will take longer or be less successful?
Do different fungus types respond differently to the same treatment?
Participants will:
Be between the ages of 0 and 18 with confirmed tinea capitis based on lab tests (microscopy and/or culture)
Receive an oral antifungal medicine called terbinafine for 4 weeks (dosing based on weight)
Attend regular checkups every 4 weeks until both scalp appearance and lab tests show the infection is gone
At each visit, participants will:
Have their scalp examined using a trichoscope
Provide scalp samples for fungal testing
Be assessed for symptoms like itching, redness, and scaling
The study will also look at how fast different signs on the scalp go away, and which of these signs are best at predicting whether the fungus is still present.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary objective is to determine the correlation between trichoscopic changes and mycological cure, defined as both KOH and culture negativity following systemic antifungal treatment with terbinafine. Secondary objectives include evaluating the timeline of regression for individual trichoscopic signs, determining whether certain dermoscopic features persist despite microbiological cure, and assessing whether specific patterns are predictive of treatment resistance. Additionally, the study aims to investigate if baseline trichoscopic scores or fungal species (e.g., Microsporum canis, Trichophyton tonsurans, T. violaceum) are associated with prolonged treatment duration or lower cure rates.
Eligible patients will receive weight-adjusted oral terbinafine therapy for four weeks and return for clinical, trichoscopic, and microbiological evaluation every four weeks thereafter until both clinical and mycological cure are achieved. At each follow-up, standardized data will be collected including clinical symptoms (e.g., erythema, scaling, hair loss), trichoscopic features (e.g., comma hairs, corkscrew hairs, black dots), and laboratory results. Trichoscopic evaluations will be recorded using handheld dermoscopy and interpreted independently by two dermatologists. Discrepancies will be resolved by a third expert reviewer.
Statistical analyses will include descriptive statistics, McNemar's test to assess pre/post-treatment trichoscopic changes, sensitivity/specificity/PPV/NPV analyses for predicting culture positivity, and Kaplan-Meier survival analysis for the regression timing of individual dermoscopic findings. Regression models will explore predictors of treatment duration and failure. A trichoscopic scoring system will also be evaluated as a tool for estimating treatment response.
All procedures will comply with the Declaration of Helsinki, and written informed consent will be obtained from legal guardians. Patient confidentiality will be maintained throughout the study. The findings are expected to enhance early treatment monitoring and guide clinical decisions using non-invasive imaging tools.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Clinical and trichoscopic findings compatible with tinea capitis
Laboratory confirmation of tinea capitis (positive potassium hydroxide \[KOH\] smear and/or fungal culture)
Eligible for systemic antifungal treatment with terbinafine
Written informed consent obtained from a parent or legal guardian
Exclusion Criteria
Negative KOH smear and negative culture
Current use of immunosuppressive therapy or presence of severe systemic illness (e.g., malignancy, HIV, organ transplant)
Contraindication to terbinafine treatment
Poor compliance or unwillingness to attend follow-up visits
Coexisting dermatologic conditions in the affected scalp area (e.g., seborrheic dermatitis, alopecia areata, lichen planus)
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istanbul Medeniyet University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tunç Ozen
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vefa Aslı Erdemir, Proffesor
Role: STUDY_DIRECTOR
medeniyet university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medeniyet University
Istanbul, Kadıköy, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Vefa Aslı Erdemir, Proffesor
Role: CONTACT
Phone: +905052685651
Email: vefaaslı@hotmail.com
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
tunnç özen, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2536854
Identifier Type: -
Identifier Source: org_study_id